Local Response and Barrier Recovery in Elderly Skin Following the Application of High-Density Microarray Patches
- PMID: 35455332
- PMCID: PMC9031416
- DOI: 10.3390/vaccines10040583
Local Response and Barrier Recovery in Elderly Skin Following the Application of High-Density Microarray Patches
Abstract
The high-density microneedle array patch (HD-MAP) is a promising alternative vaccine delivery system device with broad application in disease, including SARS-CoV-2. Skin reactivity to HD-MAP applications has been extensively studied in young individuals, but not in the >65 years population, a risk group often requiring higher dose vaccines to produce protective immune responses. The primary aims of the present study were to characterise local inflammatory responses and barrier recovery to HD-MAPs in elderly skin. In twelve volunteers aged 69−84 years, HD-MAPs were applied to the forearm and deltoid regions. Measurements of transepidermal water loss (TEWL), dielectric permittivity and erythema were performed before and after HD-MAP application at t = 10 min, 30 min, 48 h, and 7 days. At all sites, TEWL (barrier damage), dielectric permittivity (superficial water);, and erythema measurements rapidly increased after HD-MAP application. After 7 days, the mean measures had recovered toward pre-application values. The fact that the degree and chronology of skin reactivity and recovery after HD-MAP was similar in elderly skin to that previously reported in younger adults suggests that the reactivity basis for physical immune enhancement observed in younger adults will also be achievable in the older population.
Keywords: dielectric permittivity; evaporimetry; microneedles; polarisation spectroscopy; skin barrier integrity; skin reactivity; vaccination.
Conflict of interest statement
B.B. is a Vaxxas employee. D.A.M. and C.D.A. have undertaken consultant work for Vaxxas. J.H. has a royalty agreement with the company (WheelsBridge AB) making the TiVi equipment. C.D.A. is a shareholder in WheelsBridge AB. The remaining authors declare no conflict. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.
Figures




Similar articles
-
Micropuncture closure following high density microarray patch application in healthy subjects.Skin Res Technol. 2022 Mar;28(2):305-310. doi: 10.1111/srt.13131. Epub 2022 Jan 22. Skin Res Technol. 2022. PMID: 35064694 Free PMC article.
-
Safety, tolerability, and immunogenicity of influenza vaccination with a high-density microarray patch: Results from a randomized, controlled phase I clinical trial.PLoS Med. 2020 Mar 17;17(3):e1003024. doi: 10.1371/journal.pmed.1003024. eCollection 2020 Mar. PLoS Med. 2020. PMID: 32181756 Free PMC article. Clinical Trial.
-
Innate local response and tissue recovery following application of high density microarray patches to human skin.Sci Rep. 2020 Oct 28;10(1):18468. doi: 10.1038/s41598-020-75169-4. Sci Rep. 2020. PMID: 33116241 Free PMC article. Clinical Trial.
-
Hygiene and emollient interventions for maintaining skin integrity in older people in hospital and residential care settings.Cochrane Database Syst Rev. 2020 Jan 23;1(1):CD011377. doi: 10.1002/14651858.CD011377.pub2. Cochrane Database Syst Rev. 2020. PMID: 32006460 Free PMC article.
-
Impacts of Skin Eccrine Glands on the Measured Values of Transepidermal Water Loss.Cureus. 2022 Dec 6;14(12):e32266. doi: 10.7759/cureus.32266. eCollection 2022 Dec. Cureus. 2022. PMID: 36620832 Free PMC article. Review.
Cited by
-
Beyond the Needle: Innovative Microneedle-Based Transdermal Vaccination.Medicines (Basel). 2025 Feb 7;12(1):4. doi: 10.3390/medicines12010004. Medicines (Basel). 2025. PMID: 39982324 Free PMC article. Review.
-
Immunogenicity, safety, usability and acceptability of microarray patches for vaccination: a systematic review and meta-analysis.BMJ Glob Health. 2023 Oct;8(10):e012247. doi: 10.1136/bmjgh-2023-012247. BMJ Glob Health. 2023. PMID: 37827725 Free PMC article.
References
-
- Hesse E.M., Atanasoff S., Hibbs B.F., Adegoke O.J., Ng C., Marquez P., Osborn M., Su J.R., Moro P.L., Shimabukuro T., et al. Shoulder Injury Related to Vaccine Administration (SIRVA): Petitioner claims to the National Vaccine Injury Compensation Program, 2010–2016. Vaccine. 2020;38:1076–1083. doi: 10.1016/j.vaccine.2019.11.032. - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous